SEC Company Response from TuHURA Biosciences, (HURA) — May 8, 2019
TuHURA Biosciences, Inc./NV (HURA) (CIK 0001498382)
Date: May 8, 2019 · CIK: 0001498382 · Accession: 0001213900-19-007999
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-230929
Letter
Division Of Corporation Finance Office Of Healthcare & Insurance Securities And Exchange Commission Re: DelMar Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed April 18, 2019 File No. 333-230929
Dear Ms. Westbrook,
On behalf of DelMar Pharmaceuticals, Inc., (the “Company”), we are hereby responding to the letter, dated April 24, 2019 (the “Comment Letter”), from the Division of Corporation Finance, Division of Healthcare & Insurance of the Securities and Exchange Commission (the “Commission”), regarding the Company’s Registration Statement on Form S-1, filed on April 18, 2019 (the “Registration Statement on Form S-1”).
For ease of reference, set forth below in bold is the comment of the staff of the Commission (the “Staff”) with respect to the Registration Statement on Form S-1, as reflected in the Comment Letter. The Company’s response is set forth below the comment.
The Company has authorized us to respond to the Comment Letter as follows:
Registration Statement on Form S-1 filed on April 18, 2019
Cover page
1. We note your disclosure that the rights offering will expire on or about a certain date, and that you may extend the rights offering for additional periods in your sole discretion. Please revise your disclosure to provide an expiration date for the rights offering that is not indefinite. Refer to Item 501(b)(8)(iii) of Regulation S-K.
Response: The Company respectfully acknowledges the Staff’s comment, and has revised the disclosure throughout the Registration Statement on Form S-1, including on the prospectus cover page, pages 6, 10, 12, and 96, in response to the Staff’s comment, to provide an expiration date of July 20, 2019 on any extensions of the offering.
If you have any questions with respect to the foregoing, please feel free to call me at (973) 597-2476.
Very truly yours,
/s/ Steven M. Skolnick
Show Raw Text
CORRESP
1
filename1.htm
Steven M. Skolnick
Partner
1251 Avenue of the Americas
New York, New York 10020
T: 973 597 2476
F: 973 597 2477
E: sskolnick@lowenstein.com
May 8, 2019
Christine Westbrook
Division Of Corporation Finance
Office Of Healthcare & Insurance
Securities And Exchange Commission
Washington, DC 20549
Re: DelMar Pharmaceuticals, Inc.
Registration Statement on
Form S-1
Filed April 18, 2019
File No. 333-230929
Dear Ms. Westbrook,
On behalf of DelMar
Pharmaceuticals, Inc., (the “Company”), we are hereby responding to the letter, dated April 24, 2019 (the “Comment
Letter”), from the Division of Corporation Finance, Division of Healthcare & Insurance of the Securities and Exchange
Commission (the “Commission”), regarding the Company’s Registration Statement on Form S-1, filed on April 18,
2019 (the “Registration Statement on Form S-1”).
For ease of reference,
set forth below in bold is the comment of the staff of the Commission (the “Staff”) with respect to the Registration
Statement on Form S-1, as reflected in the Comment Letter. The Company’s response is set forth below the comment.
The Company has
authorized us to respond to the Comment Letter as follows:
Registration Statement on Form S-1
filed on April 18, 2019
Cover page
1. We note your disclosure that
the rights offering will expire on or about a certain date, and that you may extend the rights offering for additional periods
in your sole discretion. Please revise your disclosure to provide an expiration date for the rights offering that is not indefinite.
Refer to Item 501(b)(8)(iii) of Regulation S-K.
Response: The
Company respectfully acknowledges the Staff’s comment, and has revised the disclosure throughout the Registration Statement
on Form S-1, including on the prospectus cover page, pages 6, 10, 12, and 96, in response to the Staff’s comment, to provide
an expiration date of July 20, 2019 on any extensions of the offering.
If you have any questions
with respect to the foregoing, please feel free to call me at (973) 597-2476.
Very truly yours,
/s/ Steven M. Skolnick
Steven M. Skolnick